119 related articles for article (PubMed ID: 18566746)
1. Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status.
Cemeus C; Zhao TT; Barrett GM; Lorimer IA; Dimitroulakos J
J Neurooncol; 2008 Oct; 90(1):9-17. PubMed ID: 18566746
[TBL] [Abstract][Full Text] [Related]
2. Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110δ.
Schulte A; Liffers K; Kathagen A; Riethdorf S; Zapf S; Merlo A; Kolbe K; Westphal M; Lamszus K
Neuro Oncol; 2013 Oct; 15(10):1289-301. PubMed ID: 23877316
[TBL] [Abstract][Full Text] [Related]
3. Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation.
Acquaviva J; Jun HJ; Lessard J; Ruiz R; Zhu H; Donovan M; Woolfenden S; Boskovitz A; Raval A; Bronson RT; Pfannl R; Whittaker CA; Housman DE; Charest A
Cancer Res; 2011 Dec; 71(23):7198-206. PubMed ID: 21987724
[TBL] [Abstract][Full Text] [Related]
4. Acridine yellow G blocks glioblastoma growth via dual inhibition of epidermal growth factor receptor and protein kinase C kinases.
Qi Q; He K; Yoo MH; Chan CB; Liu X; Zhang Z; Olson JJ; Xiao G; Wang L; Mao H; Fu H; Tao H; Ramalingam SS; Sun SY; Mischel PS; Ye K
J Biol Chem; 2012 Feb; 287(9):6113-27. PubMed ID: 22215664
[TBL] [Abstract][Full Text] [Related]
5. Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells.
Li HF; Kim JS; Waldman T
Radiat Oncol; 2009 Oct; 4():43. PubMed ID: 19828040
[TBL] [Abstract][Full Text] [Related]
6. EGFRvIII uses intrinsic and extrinsic mechanisms to reduce glioma adhesion and increase migration.
Banisadr A; Eick M; Beri P; Parisian AD; Yeoman B; Placone JK; Engler AJ; Furnari F
J Cell Sci; 2020 Dec; 133(24):. PubMed ID: 33243756
[TBL] [Abstract][Full Text] [Related]
7. Determination of PDK1, SLC2A1, EGFR, PTEN, CD276 Gene Expression Levels and IDH1 Gene R132H Polymorphism in Brain Tumor Tissues.
Korkmaz S; Soylemez E; Soylemez Z; Solak M
Turk Neurosurg; 2023; 33(6):1086-1092. PubMed ID: 37528722
[TBL] [Abstract][Full Text] [Related]
8. Improving the efficacy of anti-EGFR drugs in GBM: Where we are going?
Ge M; Zhu Y; Wei M; Piao H; He M
Biochim Biophys Acta Rev Cancer; 2023 Nov; 1878(6):188996. PubMed ID: 37805108
[TBL] [Abstract][Full Text] [Related]
9. Unlocking the EGFR-mediated epitranscriptome: A pathway to novel therapies.
Gencel-Augusto J; Bivona TG
Mol Cell; 2023 Dec; 83(23):4199-4201. PubMed ID: 38065059
[TBL] [Abstract][Full Text] [Related]
10. Overcoming EGFR inhibitor resistance in Glioblastoma by targeting co-amplified genes.
Pant A; Lim M
Proc Natl Acad Sci U S A; 2023 Sep; 120(38):e2312277120. PubMed ID: 37672559
[No Abstract] [Full Text] [Related]
11. A heterogeneous pharmaco-transcriptomic landscape induced by targeting a single oncogenic kinase.
Giglio RM; Hou N; Wyatt A; Hong J; Shi L; Vaikunthan M; Fuchs H; Nima JP; Malinowski SW; Ligon KL; McFaline-Figueroa JR; Yosef N; Azizi E; McFaline-Figueroa JL
bioRxiv; 2024 Apr; ():. PubMed ID: 38645018
[TBL] [Abstract][Full Text] [Related]
12. Repositioning of HMG-CoA Reductase Inhibitors as Adjuvants in the Modulation of Efflux Pump-Mediated Bacterial and Tumor Resistance.
Schelz Z; Muddather HF; Zupkó I
Antibiotics (Basel); 2023 Sep; 12(9):. PubMed ID: 37760764
[TBL] [Abstract][Full Text] [Related]
13. Regulation of Autophagy via Carbohydrate and Lipid Metabolism in Cancer.
Alizadeh J; Kavoosi M; Singh N; Lorzadeh S; Ravandi A; Kidane B; Ahmed N; Mraiche F; Mowat MR; Ghavami S
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190124
[TBL] [Abstract][Full Text] [Related]
14. Statins and Gliomas: A Systematic Review of the Preclinical Studies and Meta-Analysis of the Clinical Literature.
Rendon LF; Tewarie IA; Cote DJ; Gabriel A; Smith TR; Broekman MLD; Mekary RA
Drugs; 2022 Feb; 82(3):293-310. PubMed ID: 35122635
[TBL] [Abstract][Full Text] [Related]
15. Pitavastatin Is a Highly Potent Inhibitor of T-Cell Proliferation.
Voss L; Guttek K; Reddig A; Reinhold A; Voss M; Simeoni L; Schraven B; Reinhold D
Pharmaceuticals (Basel); 2021 Jul; 14(8):. PubMed ID: 34451823
[TBL] [Abstract][Full Text] [Related]
16. The multifaceted NF-kB: are there still prospects of its inhibition for clinical intervention in pediatric central nervous system tumors?
Medeiros M; Candido MF; Valera ET; Brassesco MS
Cell Mol Life Sci; 2021 Sep; 78(17-18):6161-6200. PubMed ID: 34333711
[TBL] [Abstract][Full Text] [Related]
17. Statin as a Potential Chemotherapeutic Agent: Current Updates as a Monotherapy, Combination Therapy, and Treatment for Anti-Cancer Drug Resistance.
Tilija Pun N; Jeong CH
Pharmaceuticals (Basel); 2021 May; 14(5):. PubMed ID: 34065757
[TBL] [Abstract][Full Text] [Related]
18. Lovastatin-mediated MCF-7 cancer cell death involves LKB1-AMPK-p38MAPK-p53-survivin signalling cascade.
Huang SW; Chyuan IT; Shiue C; Yu MC; Hsu YF; Hsu MJ
J Cell Mol Med; 2020 Jan; 24(2):1822-1836. PubMed ID: 31821701
[TBL] [Abstract][Full Text] [Related]
19. The oncogenic roles of 27-hydroxycholesterol in glioblastoma.
Liu L; Li MY; Xing Y; Wang XY; Wang Y
Oncol Lett; 2019 Oct; 18(4):3623-3629. PubMed ID: 31579088
[TBL] [Abstract][Full Text] [Related]
20. A New Method for Ethical and Efficient Evidence Generation for Off-Label Medication Use in Oncology (A Case Study in Glioblastoma).
Agrawal S; Vamadevan P; Mazibuko N; Bannister R; Swery R; Wilson S; Edwards S
Front Pharmacol; 2019; 10():681. PubMed ID: 31316378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
